Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | APEX1 | P27695 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.83 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | IL2 | P60568 | 1/20 | 0.63 |
| ▸ | MGAM | O43451 | 1/20 | 0.62 |
| ▸ | GUSB | P08236 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoorientin SCHEMBL18605974 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL29350057 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL30098358 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL29687259 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL14076164 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL23761 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL10307522 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL22878053 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isoorientin SCHEMBL22785963 | 1.00 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB | |
| Isovitexin SCHEMBL20870220 | 0.91 | L3MBTL1 (1.00) | L3MBTL1KDM4EAPEX1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250351855-A1 | TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2025-11-20 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250041375-A1 | SUGAR CANE EXTRACTS FOR USE IN ANIMAL FEEDS | Poly Gain Pte Ltd (SG) | 2025-02-06 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20230157342-A1 | TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2023-05-25 | — | — | US | claimed |
| EP-3806652-A1 | SUGAR CANE EXTRACTS FOR USE IN ANIMAL FEEDS | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2021-04-21 | — | — | EP | claimed |
| US-20210060115-A1 | SUGAR CANE EXTRACTS FOR USE IN ANIMAL FEEDS | Poly Gain Pte Ltd (SG) | 2021-03-04 | — | — | US | claimed |
| EP-3675654-A1 | IMPROVING THE TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2020-07-08 | — | — | EP | claimed |
| US-20200196649-A1 | IMPROVING THE TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2020-06-25 | — | — | US | claimed |
| WO-2019213703-A1 | SUGAR CANE EXTRACTS FOR USE IN ANIMAL FEEDS | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2019-11-14 | — | — | WO | claimed |
| EP-2027279-A2 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | Libragen (FR) | 2009-02-25 | — | — | EP | claimed |
| WO-2007144368-A2 | WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS | LIBRAGEN (FR) | 2007-12-21 | — | — | WO | claimed |
| CN-1820743-A | Inhibitor or promoter of uridinediphosphate glucuronosyltransferase 2B (UGT2B) | HU OLIVER YOA PU (CN) | 2006-08-23 | — | — | CN | claimed |
| US-20060069042-A1 | Cytochrome P450 2C9 inhibitors | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2006-03-30 | — | — | US | claimed |
| US-20060040875-A1 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL CENTER | 2006-02-23 | — | — | US | claimed |
| US-20050238738-A1 | Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed | TSI GROUP LIMITED (HK) | 2005-10-27 | — | — | US | claimed |
| US-20050226948-A1 | Methods for enhancing the transport of glucose into muscle | TECHNICAL SOURCING INTERNATIONAL, INC. | 2005-10-13 | — | — | US | claimed |
| WO-2005084323-A2 | COMPOSITIONS OF BIO-ACTIVE COMPOUNDS FROM FENUGREEK SEED AND METHODS FOR PRODUCING SAME | TECHNICAL SOURCING INTERNATIONAL, INC. (US) | 2005-09-15 | — | — | WO | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| US-20030166583-A1 | Such as epicatechin coadministered with retinoic acid; bioavailability | HU, OLIVER YOA-PU (TW) | 2003-09-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050226948-A1 | Methods for enhancing the transport of glucose into muscle | GYS1, SLC2A3, MUSK | L3MBTL1 2198/4885KDM4E 4227/4885APEX1 3694/4885 |
| US-20030166583-A1 | Such as epicatechin coadministered with retinoic acid; bioavailability | CYP51A1, CYP2E1, CYP7A1 | L3MBTL1 4873/4885KDM4E 4575/4885APEX1 3589/4885 |
| US-20050238738-A1 | Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed | SHBG, SIK3, HGFAC | L3MBTL1 2315/4885KDM4E 4295/4885APEX1 3260/4885 |
| US-20060040875-A1 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | UGT2B7, UGT1A3, UGT2B17 | L3MBTL1 4470/4885KDM4E 3997/4885APEX1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.